Junlin Ho Sells 8,016 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) General Counsel Junlin Ho sold 8,016 shares of Scholar Rock stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $356,551.68. Following the completion of the transaction, the general counsel owned 214,553 shares in the company, valued at approximately $9,543,317.44. This represents a 3.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Scholar Rock Trading Up 3.8%

Shares of SRRK stock opened at $47.82 on Friday. The business has a 50-day moving average of $43.59 and a 200 day moving average of $37.24. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $48.28. The stock has a market capitalization of $4.88 billion, a PE ratio of -15.18 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period last year, the firm earned ($0.66) earnings per share. As a group, sell-side analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Truist Financial cut their price target on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, October 20th. Citigroup initiated coverage on Scholar Rock in a research note on Friday, January 9th. They issued a “buy” rating and a $55.00 target price on the stock. Barclays upped their price target on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. UBS Group assumed coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and an average price target of $50.14.

Institutional Trading of Scholar Rock

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Scholar Rock by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock worth $183,032,000 after acquiring an additional 53,333 shares during the period. Wellington Management Group LLP grew its stake in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after purchasing an additional 2,521,022 shares during the period. Bellevue Group AG raised its holdings in Scholar Rock by 10.1% in the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after purchasing an additional 297,242 shares in the last quarter. Eventide Asset Management LLC lifted its position in Scholar Rock by 9.5% during the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after buying an additional 251,638 shares during the period. Finally, Holocene Advisors LP purchased a new position in Scholar Rock during the third quarter valued at $91,670,000. 91.08% of the stock is owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).